Study identifier:D5252R00002
ClinicalTrials.gov identifier:NCT03556475
EudraCT identifier:N/A
CTIS identifier:N/A
A diagnostic test to develop an AECOPD identification tool through characteristic variables extracted from diagnosed AECOPD patients
Acute exacerbations of COPD
N/A
No
-
All
300
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Apr 2022 by AstraZeneca
AstraZeneca
-
This study is an observational, multi-center and cross sectional study,to develop an identification tool on purpose of differentiating COPD exacerbation from patients with respiratory symptoms in community hospitals of China.
This is an observational, multi-center and cross-sectional study to develop an AECOPD identification tool. Estimated totally 7 tertiary hospitals with experts in respiratory area will be involved as the study sites. These study sites will cover the regions of China (Eastern, Southern, Northern, Central, Western and Northeastern region), to be representative for the patient features all over the country. The patients will be enrolled in a “consecutive” way, which is, the investigators will recruit the patients who are eligible and consented to participate in this study without personal tendency. For the enrolled patients, a face to face visit between investigator and patient will be arranged. The evaluation for the symptoms and signs will be performed and the relevant data will be collected on the visit. In addition, other relevant tests (e.g. oxygen saturation, blood test, CAT, etc) and data (demographic, medical history, etc) will be collected on this visit.
Location
Location
Shenyang, China, 110001
Location
Guangzhou, China, 510515
Location
Xi'an, China, 710061
Location
Beijing, China
Location
Changsha, China
Location
Shanghai, China, 200433
Location
Xinxiang, China
Arms | Assigned Interventions |
---|---|
Disease 1 Moderate to severe COPD Patients(n=90) | - |
Disease type 2-1) Patients with Mild/moderate AECOPD (n=60) | - |
Disease type 2-2) Patients with Severe AECOPD( n=60) | - |
Disease type 3 Non-COPD Patients with high risk factors (n=90) | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.